Summary & Overview
HCPCS G0103: Prostate Cancer Screening, PSA Test
HCPCS Level II code G0103 denotes a prostate cancer screening service using the prostate specific antigen (PSA) test. Nationally, PSA screening remains a high-volume preventive service with implications for public health screening programs, primary care workflows, and laboratory billing operations. The code identifies a distinct screening encounter separate from diagnostic PSA testing and is important for tracking preventive care utilization and payer coverage policies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of payer coverage patterns, benchmark metrics, and relevant policy context for PSA screening reimbursement. The publication highlights typical sites of service, common billing modifiers, and operational considerations affecting claims adjudication. It also summarizes where practice managers and coders should look for payer-specific guidance and coding clarifications.
This summary provides clinical context for why PSA screening is coded separately, outlines expected claims workflows, and flags areas where national policy updates can affect coverage and billing. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
HCPCS Level II code G0103 represents prostate cancer screening using the prostate specific antigen test (PSA). This service is a laboratory screening test intended to detect potential prostate cancer markers in blood.
-
Service type: Prostate cancer screening laboratory test
-
Typical site of service: Outpatient clinic, physician office, or outpatient laboratory
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 58-year-old male presents to his primary care clinic for routine preventive care and requests prostate cancer screening. Per shared decision-making, the clinician orders a prostate-specific antigen test. The service is billed under G0103 for prostate cancer screening using PSA. Typical workflow: patient arrives at an outpatient clinic or physician office; registration and preventive service eligibility confirmed; clinical staff collect a blood specimen; specimen is labeled and sent to an on-site or reference laboratory; the clinician documents informed discussion of risks and benefits of PSA screening in the medical record and interprets results on follow-up. Typical site of service: outpatient office or clinic, ambulatory care, or independent laboratory collection point. Typical patient scenario: asymptomatic men aged 50–69 (or earlier for higher-risk individuals) undergoing routine screening without symptoms of prostate disease; documentation includes indication for screening and informed consent discussion.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, Separately Identifiable Evaluation and Management Service by the Same Physician on the Day of a Procedure | Use when a distinct E/M visit is documented on the same day as PSA specimen collection for G0103. |